BioCentury | Apr 15, 2013
Clinical News

Pharmadigm preclinical data

...to normal, whereas vehicle and saline-treated animals had no measurable blood flow in the area. Pharmadigm...
BioCentury | Feb 20, 2006
Company News

Inflabloc, MantiCore Pharmaceuticals Inc. deal

...were not disclosed. The combined company will have MantiCore's preclinical cobalamin bioconjugate cancer compounds and Inflabloc's...
...DHEA) combination product, which is in Phase II testing to treat Crohn's disease and hyperlipidemia. Inflabloc Pharmaceuticals Inc....
BioCentury | Aug 30, 2004
Company News

Inflabloc inflammation, autoimmune news

...a $3 million series B financing round, the company changed its name to Inflabloc from Pharmadigm...
...II trial of its lead compound, a dehydroepiandrosterone (DHEA) combination product, to treat Crohn's disease. Inflabloc Pharmaceuticals Inc....
BioCentury | Nov 24, 2003
Company News

StemCells management update

...Business: Gene/Cell therapy Hired: Barbara Araneo as VP of development, formerly SVP of R&D at Pharmadigm...
BioCentury | Sep 3, 2002
Company News

Hollis-Eden, Pharmadigm deal

...HEPH gained exclusive global rights to certain undisclosed patents from Pharmadigm and the University of Utah...
...a focus on HIV/AIDS, malaria and hepatitis B. Hollis-Eden Pharmaceuticals Inc. (HEPH), San Diego, Calif. Pharmadigm...
BioCentury | Aug 29, 2002
Company News

HEPH, Pharmadigm licensing deal

...Hollis- Eden Pharmaceuticals (HEPH) received exclusive global rights to certain patents from Pharmadigm (Salt Lake City...
BioCentury | Jan 14, 2002
Finance

Hat in Hand?

...$15.0M Spotfire $15.0M Inhibitex $15.0M Neuron $12.2M BioNumerik $12.0M Withdrew IPO on 11/01 Xanthon $12.0M Pharmadigm...
BioCentury | Dec 3, 2001
Company News

Altea Development Corp. board of directors update

...Corp., Atlanta, Ga. Business: Drug delivery Appointed: Ned Weinshenker, president, CEO, and a director of Pharmadigm...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...$13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon $12.0M Pharmadigm...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...$13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon $12.0M Pharmadigm...
Items per page:
1 - 10 of 22
BioCentury | Apr 15, 2013
Clinical News

Pharmadigm preclinical data

...to normal, whereas vehicle and saline-treated animals had no measurable blood flow in the area. Pharmadigm...
BioCentury | Feb 20, 2006
Company News

Inflabloc, MantiCore Pharmaceuticals Inc. deal

...were not disclosed. The combined company will have MantiCore's preclinical cobalamin bioconjugate cancer compounds and Inflabloc's...
...DHEA) combination product, which is in Phase II testing to treat Crohn's disease and hyperlipidemia. Inflabloc Pharmaceuticals Inc....
BioCentury | Aug 30, 2004
Company News

Inflabloc inflammation, autoimmune news

...a $3 million series B financing round, the company changed its name to Inflabloc from Pharmadigm...
...II trial of its lead compound, a dehydroepiandrosterone (DHEA) combination product, to treat Crohn's disease. Inflabloc Pharmaceuticals Inc....
BioCentury | Nov 24, 2003
Company News

StemCells management update

...Business: Gene/Cell therapy Hired: Barbara Araneo as VP of development, formerly SVP of R&D at Pharmadigm...
BioCentury | Sep 3, 2002
Company News

Hollis-Eden, Pharmadigm deal

...HEPH gained exclusive global rights to certain undisclosed patents from Pharmadigm and the University of Utah...
...a focus on HIV/AIDS, malaria and hepatitis B. Hollis-Eden Pharmaceuticals Inc. (HEPH), San Diego, Calif. Pharmadigm...
BioCentury | Aug 29, 2002
Company News

HEPH, Pharmadigm licensing deal

...Hollis- Eden Pharmaceuticals (HEPH) received exclusive global rights to certain patents from Pharmadigm (Salt Lake City...
BioCentury | Jan 14, 2002
Finance

Hat in Hand?

...$15.0M Spotfire $15.0M Inhibitex $15.0M Neuron $12.2M BioNumerik $12.0M Withdrew IPO on 11/01 Xanthon $12.0M Pharmadigm...
BioCentury | Dec 3, 2001
Company News

Altea Development Corp. board of directors update

...Corp., Atlanta, Ga. Business: Drug delivery Appointed: Ned Weinshenker, president, CEO, and a director of Pharmadigm...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...$13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon $12.0M Pharmadigm...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...$13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon $12.0M Pharmadigm...
Items per page:
1 - 10 of 22